Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
67 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Show Display Options
RSS Create an RSS feed from your search for:
gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Condition: Breast Cancer
Intervention: Drug: Pegylated liposomal doxorubicin
2 Recruiting Pre-operative Zoledronate in Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Zoledronate
3 Recruiting DIG-HIF1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Digoxin
4 Recruiting TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: TDM1;   Drug: Lapatinib;   Drug: Abraxane
5 Recruiting Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer
Conditions: Primary Breast Cancer ER+ve;   Primary Breast Cancer AR+ve TNBN
Interventions: Drug: Enzalutamide;   Drug: Exemestane
6 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel;   Drug: Pertuzumab
7 Not yet recruiting Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer (IBC).
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
8 Recruiting A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel
9 Recruiting Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions: Drug: Paclitaxel;   Drug: Alisertib
10 Recruiting Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Anastrozole;   Drug: Anastrozole+Fulvestrant;   Drug: Tamoxifen
11 Recruiting A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Epirubicin+Cyclophosphamide;   Drug: liposomal-doxorubicin+Cyclophosphamide
12 Recruiting Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer
Condition: Operable Breast Cancer
Intervention: Drug: 0.5% lignocaine 60mM
13 Recruiting FDHT PET and Bicalutamide in Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Bicalutamide;   Procedure: FDHT PET
14 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
15 Recruiting Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil™ in Advanced Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Biological: Vigil™;   Drug: Durvalumab (MEDI4736)
16 Recruiting Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Conditions: Breast Neoplasms;   Triple Negative Breast Neoplasms
Interventions: Drug: Dasatinib;   Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis
17 Recruiting A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: PM01183
18 Not yet recruiting Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism
Condition: Breast Cancer
Intervention: Drug: Capecitabine
19 Recruiting CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
Conditions: Metastatic Breast Adenocarcinoma;   Breast Cancer
Intervention: Drug: CR1447
20 Not yet recruiting Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Conditions: Breast Cancer Female NOS;   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer;   Tubular Breast Cancer Stage III
Interventions: Drug: Denosumab;   Drug: nab-Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Trastuzumab;   Drug: Pertuzumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.